- Home
- ONCO vs APVO Comparison
ONCO vs APVO Comparison
Compare ONCO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- APVO
- Stock Information
- Founded
- ONCO 2018
- APVO 2016
- Country
- ONCO United States
- APVO United States
- Employees
- ONCO N/A
- APVO N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- ONCO Health Care
- APVO Health Care
- Exchange
- ONCO Nasdaq
- APVO Nasdaq
- Market Cap
- ONCO 1.8M
- APVO 4.1M
- IPO Year
- ONCO 2022
- APVO N/A
- Fundamental
- Price
- ONCO $4.77
- APVO $3.23
- Analyst Decision
- ONCO
- APVO Strong Buy
- Analyst Count
- ONCO 0
- APVO 1
- Target Price
- ONCO N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- ONCO 226.4K
- APVO 6.7M
- Earning Date
- ONCO 06-12-2025
- APVO 08-07-2025
- Dividend Yield
- ONCO N/A
- APVO N/A
- EPS Growth
- ONCO N/A
- APVO N/A
- EPS
- ONCO N/A
- APVO N/A
- Revenue
- ONCO $1,925,313.00
- APVO N/A
- Revenue This Year
- ONCO N/A
- APVO N/A
- Revenue Next Year
- ONCO N/A
- APVO N/A
- P/E Ratio
- ONCO N/A
- APVO N/A
- Revenue Growth
- ONCO 153.70
- APVO N/A
- 52 Week Low
- ONCO $3.82
- APVO $2.81
- 52 Week High
- ONCO $1,190.00
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- ONCO 43.03
- APVO 34.28
- Support Level
- ONCO $3.92
- APVO $2.81
- Resistance Level
- ONCO $5.10
- APVO $13.11
- Average True Range (ATR)
- ONCO 0.75
- APVO 1.10
- MACD
- ONCO 0.03
- APVO 0.30
- Stochastic Oscillator
- ONCO 24.80
- APVO 4.08
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.